Nalidixic acid is a quinolone
antibacterial abettor for articulate administration. Nalidixic acid has
apparent antibacterial action adjoin gram-negative bacilli including
Enterobacter species, Escherichia coli, Morganella Morganii; Proteus Mirabilis,
Proteus vulgaris, and Providencia rettgeri. Pseudomonas breed are about
aggressive to the drug. Nalidixic acid is antibacterial and is able over the absolute
urinary pH range. Conventional chromosomal attrition to nalidixic acid taken in
abounding dosage has been appear to appear in about 2 to 14 percent of patients
during treatment; however, bacterial attrition to nalidixic acid has not been
apparent to be communicable via R factor.
Nalidixic acid is 93% apprenticed to
protein in the blood, and the alive metabolite, hydroxynalidixic acid is 63%
bound.